AGI-1067, is a novel small molecule with anti-oxidant and anti-inflammatory properties that was discovered by AtheroGenics and designed to treat atherosclerosis of the blood vessels of the heart, or coronary...
- Mechanism
- Curator reviewed
AGI-1067 works by inhibiting key oxidant signals within cells of blood vessel walls that generate inflammatory processes that are key to the pathogenesis of atherosclerosis. This includes inhibition of inflammatory cytokines, chemokines and vascular adhesion molecules that participate in the initiation, growth and eventual destabilization of the plaque. Its anti-oxidant properties also play a role in its ability to inhibit the formation of oxidized LDL, a critical component in the formation of atherosclerotic plaque.
- Primary indication
- Investigated for use/treatment in atherosclerosis, coronary artery disease, diabetes mellitus type 2, and in-stent restenosis.Curator reviewed
- Formula / weight
- C35H52O5S2 · 616.914 g/mol (avg)
- Code names
- AGI-1067
Resolves to
RKSMVPNZHBRNNS-UHFFFAOYSA-NSMILESCC(C)(C)C1=CC(SC(C)(C)SC2=CC(=C(OC(=O)CCC(O)=O)C(=C2)C(C)(C)C)C(C)(C)C)=CC(=C1O)C(C)(C)CWhat you can answer from here — as of May 10, 2025
Which drugs share a target with Succinobucol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account